Table 5.

Evaluation of the Potential Interaction of CaM With Sex, Age, and Baseline Cardiovascular Risk on the Risk of Nonfatal Ischemic Stroke

Current Use of CaM	Cases (%) n=2690	Controls (%) n=19 538	Nonadjusted ORa (95% CI)	Adjusted ORb (95% CI)
Sex
Male	13 (0.93)	45 (0.44)	2.09 (1.12–3.89)	1.77 (0.92–3.42)
Female	37 (2.87)	248 (2.67)	1.08 (0.76–1.54)	1.04 (0.73–1.50) Test for interaction, P=0.164
Age
<70 y	11 (1.20)	71 (1.06)	1.13 (0.59–2.15)	1.11 (0.56–2.21)
≥70 y	39 (2.20)	222 (1.73)	1.28 (0.91–1.81)	1.19 (0.84–1.70) Test for interaction, P=0.860
Cardiovascular risk
Low‐intermediate	28 (1.91)	219 (1.57)	1.23 (0.82–1.83)	1.09 (0.73–1.64)
High	22 (1.80)	74 (1.32)	1.34 (0.83–2.18)	1.21 (0.73–2.00) Test for interaction, P=0.752

CaM indicates calcium supplements as monotherapy; CI, confidence interval; OR, odds ratio.

^aAdjusted only for matching factors (age, sex, and calendar year).

^bAdjusted for matching factors and for the variables described in Methods and Table 1.